Showing results (11-20 of 447) with videos related to
Sort By:
Pageof 45
The American Journal of Cardiology|July 15, 1987
Secondary prevention trials after acute myocardial infarctionC D FurbergPreventive Medicine|January 1, 1991
Organizing multicenter trials: lessons from cardiovascular prevention trialsC D FurbergThe American Journal of Cardiology|August 15, 1996
Cost-effectiveness of pravastatin in secondary prevention of coronary artery diseaseT Ashraf, J W Hay, B Pitt, et al.Circulation|September 27, 2000
Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT InvestigatorsB Pitt, R P Byington, C D Furberg, et al.The American Journal of Cardiology|November 14, 1997
Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT)R P Byington, M E Miller, D Herrington, et al.Journal of Internal Medicine|September 29, 2001
Developing an optimal approach to global drug safetyR Balkrishnan, C D FurbergThe American Journal of Cardiology|July 11, 1988
Effect of drug therapy on survival in chronic congestive heart failureC D Furberg, S YusufDrugs & Aging|September 18, 1998
Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studiesM Pahor, C D FurbergCirculation|November 1, 1995
Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention ProgramR P Byington, J W Jukema, J T Salonen, et al.Pageof 45